Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in phase 3 testing.

Pelacarsen sodium is under clinical development by Novartis and currently in Phase III for Cardiovascular Disease. According to GlobalData, Phase III drugs for Cardiovascular Disease have a 38% phase ...

Novartis, with its partner Ionis, will have the first results from an Lp(a)-lowering drug, pelacarsen. Novartis expects to have the results of that study in 2025. Other companies, like Verve ...

Novartis’ Akcea-partnered pelacarsen and Amgen’s olpasiran are both in phase 3 development, meaning they could reach the market in a couple of years. That’s important, as Lp(a) increases the ...

It gives patients hope.” One of those experimental drugs is called pelacarsen, from drugmaker Novartis. Earlier studies showed it significantly drove down Lp(a) levels in 98% of people taking it.

The revenue for Pelacarsen Sodium is expected to reach an annual total of $269 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...

such as the expected pelacarsen readout. The reaffirmed Market Perform rating and price target suggest a steady outlook for Novartis shares according to BMO Capital's analysis. In other recent ...

The analyst highlighted the early adoption of key Novartis products, such as Kisqali, Scemblix, and Pluvicto, as significant drivers of the stock's recent momentum. Moreover, the anticipated positive ...